Similar articles for PMID: 25000516

Year	Number of Results
1982	1
1999	1
2002	1
2003	1
2005	2
2006	1
2007	1
2008	3
2009	7
2011	4
2012	4
2013	8
2014	9
2015	13
2016	13
2017	12
2018	7
2019	3
2021	1
2022	2
2024	0

1

NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.

Cheong HS, Koh Y, Ahn KS, Lee C, Shin HD, Yoon SS. Cheong HS, et al. Pharmacogenet Genomics. 2014 Sep;24(9):436-41. doi: 10.1097/FPC.0000000000000072. Pharmacogenet Genomics. 2014. PMID: 25000516

2

Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.

Aksoy P, Zhu MJ, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW, Wieben ED, Yee VC, Weinshilboum RM, Wang L. Aksoy P, et al. Pharmacogenet Genomics. 2009 Aug;19(8):567-76. doi: 10.1097/FPC.0b013e32832c14b8. Pharmacogenet Genomics. 2009. PMID: 19623099 Free PMC article.

3

Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.

Jordheim LP, Nguyen-Dumont T, Thomas X, Dumontet C, Tavtigian SV. Jordheim LP, et al. Drug Metab Dispos. 2008 Dec;36(12):2419-23. doi: 10.1124/dmd.108.023184. Epub 2008 Sep 5. Drug Metab Dispos. 2008. PMID: 18775979

4

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K. Falk IJ, et al. Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9. Am J Hematol. 2013. PMID: 23873772 Free article.

5

SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.

Kim JH, Lee C, Cheong HS, Koh Y, Ahn KS, Kim HL, Shin HD, Yoon SS. Kim JH, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):533-40. doi: 10.1007/s00280-016-3103-x. Epub 2016 Jul 15. Cancer Chemother Pharmacol. 2016. PMID: 27422302 Clinical Trial.

6

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Mitra AK, et al. J Pharmacol Exp Ther. 2011 Oct;339(1):9-23. doi: 10.1124/jpet.111.182873. Epub 2011 Jun 28. J Pharmacol Exp Ther. 2011. PMID: 21712425 Free PMC article.

7

5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.

Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D; “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group). Díaz-Santa J, et al. Eur J Haematol. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. Epub 2022 Sep 16. Eur J Haematol. 2022. PMID: 36063368

8

Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population.

Lee MK, Cheong HS, Koh Y, Ahn KS, Yoon SS, Shin HD. Lee MK, et al. Genet Test Mol Biomarkers. 2016 Nov;20(11):696-701. doi: 10.1089/gtmb.2016.0007. Epub 2016 Sep 9. Genet Test Mol Biomarkers. 2016. PMID: 27610459

9

Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).

Zhu KW, Chen P, Zhang DY, Yan H, Liu H, Cen LN, Liu YL, Cao S, Zhou G, Zeng H, Chen SP, Zhao XL, Chen XP. Zhu KW, et al. J Transl Med. 2018 Apr 10;16(1):90. doi: 10.1186/s12967-018-1463-1. J Transl Med. 2018. PMID: 29631596 Free PMC article.

10

Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.

Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, Kawai H, Sato A, Miyamoto M, Toyosaki M, Machida S, Kojima M, Shirasugi Y, Kawada H, Ogawa Y, Ando K. Amaki J, et al. Int J Hematol. 2015 Jun;101(6):543-53. doi: 10.1007/s12185-015-1766-4. Epub 2015 Mar 4. Int J Hematol. 2015. PMID: 25735499

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

82 results

Results by year